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Abstract 
We propose a general Bayesian network model for 
application in a wide class of problems of therapy 
monitoring. We discuss the use of stochastic 
simulation as a computational approach to 
inference on the proposed class of models. As an 
illustration we present an application to the 
monitoring of cytotoxic chemotherapy in breast 
cancer. 
1. INTRODUCTION 
Of interest here is the general problem of monitoring and 
controlling a biomedical process over time. The basic 
premise is that a model of the process of interest is 
available, which allows learning from past data and 
predicting the future evolution of the process. Such a 
model may provide an intelligent system with a basis for 
(a) 
(b) 
activating alarms which indicate significant 
deviations from expected progress ; 
using the accumulating data about the process 
to "learn" about the model parameters, for a 
more sensitive monitoring and for more 
accurate patient-specific predictions; 
In this paper we propose a model structure that appears to 
be generic to the monitoring problem, and therefore likely 
to be useful in a wide class of clinical monitoring 
problems. Typical applications may involve short-term 
drug delivery, or medium term treatment, or long-term 
monitoring of chronic disease. In drug delivery the process 
of interest is the temporal variation of the drug 
concentration in body compartments, and the goal is to 
suggest dosage adjustments that are necessary to achieve 
concentrations which lie between specific desired limits. 
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In the management of a chronic disease the monitored 
process is typically the patient's progression through 
stages of the disease, and the goal of the monitoring is to 
predict possible risks and benefits of changes in therapy. 
An application to medium-tenn treatment monitoring is 
used in this paper as an illustration.Ciinical practice in 
medium- or long-term monitoring situations often 
involves simple rules in which an observed change in the 
process provokes a corresponding action. Usually these 
rules are grossly inappropriate for particular patients. Our 
approach should allow a progress with respect to such a 
scheme, in that the rules would be replaced by an adaptive 
model, or the model might be used to evaluate the 
reliability of the rules. 
In the field of drug dosage individualization a Bayesian 
approach has previously been suggested (eg. D'Argenio 
1988, Sheiner 1982). However a flexible framework for 
model development and for inference computations in this 
area has not previously been proposed. 
In this paper we use a Bayesian network both as a 
representation of the model and as a computational 
framework for inference. Bayesian networks are able to 
crystallize in a graphical representation the rich mixture of 
causal knowledge and conditional independence 
assumptions that underlies a complex probabilistic model. 
At a high level, the network will display the way in 
which the basic sub-systems relate and interlock to form 
the complete mosaic that represents the process of 
interest. This is particularly useful in models that involve 
development over time. At a lower level, the network will 
display in detail the conditional independence relationships 
among individual variables in each portion of the global 
model. 
The computation of inferences on the model can be 
conveniently performed using a stochastic simulation 
algorithm, called the Gibbs sampler [Geman & Geman, 
1984] [Pearl, 1987] [Gelfand, 1988] [Henrion, 1990] 
[Shachter, 1990]. The essence of this algorithm consists 
of sampling the joint posterior distribution of unobserved 
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variables/parameters in the model. The result is an 
approximation of the desired posteriors. 
In alternative, one might use algorithm for the exact 
calculation of posteriors (see, for example, Lauritzen and 
Spiegelhalter, 1988). However, algorithms for "exact" 
probability propagation may raise difficulties in certain 
situations. The first is when the graph is too tightly 
connected, which will particularly occur when population 
parameters are not precisely specified. The second is when 
continuous variables are involved: "exact" propagation 
currently requires that these variables are discretized, and a 
recent proposed "exact" method for propagating 
probabilities on networks with mixed qualitative and 
quantitative variables [Lauritzen, 1990] seems to assume 
heavy restrictions on the distributions involved. A 
compile-time discretization may be hampered by the 
difficulty of deciding the most appropriate binning and 
bounding; a run-time ("dynamic") discretization may led 
to a significant overhead, particularly if the involved 
distributions are complex. 
Thanks to the availability of standard routines for 
sampling from continuous distributions [Ripley, 1987], 
stochastic simulation takes advantage of what we know to 
hamper the applicability of exact methods, namely the 
continuous nature of the variables, particularly non­
Gaussian distributions. 
responses 
abstraction, a node at a given level representing one or 
more nodes at lower levels. This greatly facilitates insight 
into the model. 
In this section we consider a top-level view of our model, 
which is shown in Fig. I. 
We suppose that a response relationship of interest has 
been observed on N cases, typically patients, that are 
somehow similar. The N-th patient, called the target case, 
is currently under observation. Node X represents future 
evolution of the target case, conditional on a plan for 
future therapeutic action. 
Usually there will be a substantial patient heterogeneity 
in their response to the therapy, and part of this variation 
will be "explained" by a set z of covariates (eg. age, sex) 
that affect an individual's response characteristics. We let 
Zi denote the covariate vector for the i-th patient. To 
handle patient heterogeneity, we introduce patient-specific 
unknown response parameter vectors, 81, ... ,9t-1. We regard 
the generic 8i as drawn from a density p(8i lzi,f3,K"), 
where the unknown parameters f3 represent effects 
associated with the individual covariates, and K" is a 
vector of distributional parameters. For notational 
economy we pool f3 and K", which we call the 
hyperparameters, into a single parameter vector tc =(f3,K"), 
Figure 1. High-level view of the general Bayesian network model for therapeutic monitoring 
2. HIGH-LEVEL VIEW OF THE 
MODEL 
One of the advantages of Bayesian networks is that they 
can be developed at progressively higher levels of detail. 
One then obtains network models at different levels of 
called the hyperparameter vector. We assume that the 
generic 8i completely defines the response characteristics 
for the i-th patient. 
Therefore, the vector of the actual observations on the 
response of the i-th patient, denoted as Yi· can be viewed 
as a random vector drawn from the density p(yi 
IBi,ci),where the vector ci summarizes the known values 
of a set of context variables, describing contingent 
conditions such as dose schedules, observation times, or 
contingent aspects of the patient such as, for example, 
values of physiological quantities at drug administration. 
3. INFERENCE 
The inference procedure starts with using "population" 
information : 
to shape a prior distribution for the unknown parameters 
� for the target case. Then, case-specific response data 
(YN ,eN) are used to update such prior into a posterior 
distribution that reflects all the current information about 
the target case, while "borrowing strength" from the 
whole past experience D. A classical maximum­
likelihood approach tends to yield a poor estimate of � 
or of linear transformations of it if the record (YN ,eN) 
contains poor information. By contrast, in our approach 
the estimates of those components or transformations of 
� which are poorly estimated from the patient's-specific 
data will be drawn towards the population average, so that 
more reasonable values should be obtained. 
A further benefit of our approach is that the estimation of 
� is done through a sequential updating procedure : as 
new data from the monitored patient (or from data-base 
patients) become available they are incorporated to yield a 
revised posterior distribution of BN, and thus a revised 
predictive distribution of X. Significant changes in the 
patient's behaviour, possibly pointing to important 
patho-physiological events, should be mirrored by 
concomitant patterns of change of the posterior of �-
The inference involves four basic steps of probability 
propagation over the net of Fig.!. These steps are 
separately described in the following. Below the 
description of each single step, the relevant portion of the 
net of Fig. I is shown. 
population updating: initially we pretend to be 
completely uninformed about the value of the 
hyperparameters n, and represent this "ignorance" by 
associating with node 1r a "vague" hyper  pr ior  
distribution, denoted p0(n). Then information D 
=(y1, ... ,yN-I•ZJ,···•ZN-l•cl, ... ,CN-Il is used to 
update p0(n), using probability propagation over the 
network below, into an a posteriori distribution PI (n 
ID), called the population distribution of n ; 
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coll apsing: prior to considering the specific data 
(YN ,eN), all we know about the target case is the 
corresponding covariate vector ZN and the fact that 
he/she/it is a member of the same population from 
which the remaining N-1 data base cases were drawn. 
This leads to regard the parameters � for the target 
case as those of a generic population individual with 
covariables ZN, and to view BN as drawn from the 
distribution : 
Po(�lzN,D)= JPe(�llt",ZN)p1(�r ID) dm (1) 
n 
where n denotes relevant domain of n. 
case-specific updating past data {YN ,eN ) 
obtained from the target case are used to update the 
prior Po(�lzN,D) into a posterior distribution p1(�1 
ZNJ'N,eN,D) which, by Bayes' theorem, is given by: 
PJ (�I ZNJ'N,eN,D) oc Po(�lzN,D) X p<JN l�,eN) 
(2) 
and that describes our uncertainty about the response 
parameters for the target case, after considering all 
relevant (population- and patient-specific) available 
information. 
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prediction: p1 (8NI zN,yN,cN,D) is used to obtain a 
predictive distribution of X, denoted pp(X ). Future 
patient's evolution is predicted under different 
hypothesized decision plans for a more rational 
decision. pp(X ) is defined by : 
pp(X ) = V(L;; p(X I�)PJ(�I ZN,JN,cN,D) d� 
(3)) 
where L denotes relevant domain of �· 
4. COMPUTING THE INFERENCES VIA 
STOCHASTIC SIMULATION 
The computations required in the above described inference 
phases can be conveniently performed by sampling 
techniques. For example, collapsing requires the 
integration (1). This can be performed by first drawing a 
sample n<0) from p1 (n ID), then a sample fi..O) from 
Pa(�IJ1.0l,z;N), then a new sample ?fl) from p1 (n ID) 
and a new sample fi..l) from pe(� ltt1 l,zN), and so on. 
This resampling is repeated a high number of times, say 
L. At the end, one can straightforwardly use the set of 
generated samples { fi..O) ,fi..l) , ... ,fi..L)) to calculate any 
marginal or summary of Po(8NIZN,D), eg. selected 
percentiles of the distribution of a given component of 
�· 
Note that the densities that appear in (1)-(2) are 
multivariate, which seems to imply that the sampling 
steps involved in collapsing and case-specific updating 
must be actually performed on multivariate densities. As a 
matter of fact, one may draw samples from a multivariate 
distribution by actually sampling univariate distributions. 
A first possibility is to exploit conditional independence. 
For example, if the components of n are conditionally 
independent given D, then one can draw samples from the 
multivariate density p1 (n ID) by actually sampling 
individual densities Pl (nh ID). 
Case-specific updating and prediction are conveniently 
carried out by an iterative stochastic simulation 
algorithm, called the Gibbs sampler, that uses a Bayesian 
network representation of the relationships among 
variables (�.ZN.JN,CN) as the computational framework 
for the necessary calculations. Such a network will 
obviously depend on the specific application, since it 
describes in all details the structure of the conditional 
independencies among individual variables in the problem. 
Perhaps the key reference to Gibbs sampling is Geman & 
Geman [Geman & Geman, 1984], who discuss its 
application to image analysis. A thorough review of the 
method is given by Gelfand & Smith [Gelfand, 1988]. 
Within the AI literature, the method has been explored, 
under the name of Markov stochastic simulation, by 
several authors, eg. Pearl [Pearl, 1987] and Henrion 
[Henrion, 1990]. 
To perform the Gibbs sampling, initial values are 
assigned to each unobserved variable in the network. 
Then, for each unobserved variable in tum, the current 
value is replaced by a value drawn from the full 
conditional distribution of that variable given the current 
values of its "neighbours" in the net (parents, children and 
parents of the children, observed and unobserved). This 
resampling is repeated many times. Under certain 
regularity conditions, Geman & Geman [Geman & 
Geman, 1984] show that the resampling process is an 
irreducible Markov chain that converges to an equilibrium 
distribution given by the full posterior distribution of the 
unknown variables. Thus, after the sampling, any 
posterior summaries or marginal components of such 
multivariate posterior can be straightforwardly calculated 
from the set of generated samples. · 
5. S PECIFIC MO DEL FO R 
CYTOTOXIC CHEMOTHE R APY 
MON ITORING IN BREAST CANCER 
As an illustration example, we consider an application to 
the monitoring of patients affected by breast-cancer who 
are being given cycles of post-operative cytotoxic 
chemotherapy. From a clinical perspective, it is desirable 
that the patient receives an adequate dose, while guarding 
excessive toxicity which leaves the patient vulnerable to 
bouts of infection. 
We need a low-level network model that describes the 
relationships among individual response parameters, 
context variables and response observations in this 
specific application. The idea is one of introducing 
suitable and reasonable conditional independence 
assumptions among the variables in order that the 
problem can be decomposed into manageable sub­
problems, and that subsequent quantification of the model 
is straightforward. 
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Figure 2. Intennediate-Ievel view of a Bayesian network for the monitoring of cytotoxic 
chemotherapy in breast cancer. The figure shows only a portion of model for the generic i-th 
patient. A big shaded arrow pointing from a layer to another means that each node in the first layer 
sends an arrow to each node in the latter Ia yer. 
log(WBC) 
toj j 
Figure 3. log-WBC-count profile over j-th cycle for a 
generic patient 
Our proposed model, which has been described in more 
detail by Bellazzi et al (1991), is shown in Fig.2. This 
model represents the assumption that observations on 
individual cycles of treatment are conditionally 
independent given some patient -specific parameters, such 
as those representing the sensitivity and responsiveness of 
the patient. 
of the log-WBC-count profile over the generic treatment 
cycle. 
The intercept w0j represents the log-WBC count at drug 
administration. The downward slope is denoted as Aj. the 
recovery rate as r (assumed independent of the cycle) and 
the change point as l'j- The minimum log-WBC level 
reached during the cycle j, denoted as Wj, is a simple 
function of ( w0j, Aj. 't'j } . 
By adding gaussian white noise errors ekj• k =1, ... , 5; 
j= 1 , ... , N C, w e  obtain the following longitudinal 
regression model for the log-WBC profile over treatment 
cycle j : 
Aj = k x dosej x a 
coj = w0j - k x dosej x a x -r (4) 
wkj = w0j - A.j x (tkj -toj) + ekj if 0 <tkj<-r 
wkj = coj+(r -coj)(l-exp(-yx(tkj -'t')})+ekj if 't'<tkj 
ekj - No(O, 112) 
We assume that the level of white blood cell (WBC ) with : 
count is the most important aspect of bone-marrow 
toxicity. High toxicity is reflected by a low WBC count. k 
Several features might be straightforwardly combined with j 
the WBC count in our model, but nothing essential is ekj lost if we restrict to a simple model. We let Wkj denote 
k-th log-WBC-count measurement within the j-th cycle of dosej treatment, and let tk j  denote the time of this 
measurement, taken from the instant at which the drug is 
administered at the beginning of the cycle. The stylized 
profile shown in Fig. 3 is assumed to be a realistic model 
observation within cycle (k = 1 , ... ,5) 
cycle number 
realisation of a gaussian random variable with 
mean 0 and variance d2; 
standardized dose = actual dose given to the 
patient at cycle j divided by square meters of 
body surface area ; 
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a 
k 
r 
patient's sensitivity to the drug (a =1 : normal 
patient; a =1.5 : sensitive patient; a =2 : very 
sensitive patient ) ; 
expected fall in the log-WBC count count in 
unit time, for a normal patient given a unit 
dose of treatment ; 
"normal" log-WBC count (the value at the 
start of the therapy). 
The parameters n.m, m =1, ... , 3 are hyperparameters. 
The parameter a is more conveniently treated as 
continuous. A suitable class of prior distributions for a 
is the inverse gamma : 
1/a - r(a , b) (7) 
eN 
Figure 4 Bayesian Network representation of our patient-model for toxicity. Layers (from top to 
bottom) contain : hyperparameters, response parameters, response observations (WBC counts), 
context variables. A big shaded arrow pointing from a layer to another means that each node in the 
first layer sends an arrow to each node in the Iauer layer. 
From (4) it follows that the conditional distribution 
attached to the generic observed log-WBC-count wkj is 
gaussian, and specified by : 
p(wkjl all other variables)= 
=No(woj- k dosej a(tkj-toj),�) if 'I"j <tkj (5) 
=No( mj+(r -mj)( l -exp{ -rx(tkj --r )}),�) if'I"j :2:tkj 
A complete Bayesian formulation of the model requires us 
to specify conditional distributions of response 
parameters { a, r , -r , a } given a suitable set of 
hyperparameters. We decided to take a, r, -r as 3-level 
discrete random variables with respective prior probability 
mass functions: 
p(a =m )=nam, p(r=m )=nrm• p(-r =m )=nTm (6) 
m =1, ... , 3 
which preserves conjugacy with respect to (5). The 
quantities a , b are hyperparameters. 
Finally we need to attach prior distributions to the 
hyperparameters. A suitable prior for each hyperparameter 
is the uniform distribution over a suitable interval. Such a 
"vague" hyperprior expresses our a priori total ignorance 
about such hyperparameters. 
The qualitative relationships implicit in equations (4)-(7) 
are depicted in the Bayesian Network shown in Fig. 3. 
The meaning of a generic arrow x -->y may be interpreted 
to be "x contributes to define the distribution from which 
y is generated". The distributional specifications described 
above provide a complete quantification of the network, in 
that they specify the conditional distribution of each 
random variable given its parents in the network. 
Note that the network contains a node for each single 
observation on WBC. Implicit in the network structure is 
the assumption that these observations are conditionally 
independent given the response parameters and the context 
variables. This is correct as long as one neglects 
correlation among errors ekj· 
One could acknowledge the fact that response parameters 
may vary from cycle to cycle by introducing cycle specific 
parameters aj• OJ and so on, and impose a structure (eg. 
a time series model) that expresses the temporal 
relatedness among these, but we shall not pursue this 
here. 
5.3 Numerical results 
A computer program, called GAMEES (Bellazzi, 1991), 
has been developed for general purpose Bayesian network 
modelling and inference using stochastic simulation. The 
network structure is entered into the computer through a 
graphical interface. The program requests the user to enter 
only essential aspects of the overall multi-level network 
structure. The program then internally generates all the 
implied repetitive structure. GAMEES incorporates a wide 
library of sampling routines and sampling control 
strategies for carrying out all the inference steps described 
in section 3 and processing the generated samples. The 
population-updating phase is carried out through a 
connection between the Bayesian network and a patient 
data-base. 
By means of GAMEES, we applied the model of Fig.3 to 
the treatment records of I I  patients undergoing breast­
cancer post-operative chemotherapy. These records 
contained data from 2 to 3 treatment cycles per patient, 
each cycle yielding at most 5 data points. 
Population updating and collapsing yielded population 
priors for response parameters. In particular, for parameter 
a we obtained : Pl (a =1 )= 0.33 and Pl (a=l5 )= 0.36 
and PI (a=2 )= 0.3I, indicating that patients with 
"normal" sensitivity are slightly more frequent than 
others. 
The data from the chosen target patient spanned 5 
treatment cycles. Fig.5a shows the data from the target 
patient superimposed to a "cloud of points" that 
represents a collection of profiles simulated using 
population distributions for the response parameters. The 
profiles appear to be very dispersed, reflecting high 
heterogeneity within the population. It is apparent that 
the target patient is much more sensitive than the 
population average, and that a prediction of the response 
for the target patient based on population distributions of 
the unknown model parameters would be inappropriate. 
Patient-specific updating was first carried out on the basis 
of first cycle data from the target patient. 500 Gibbs 
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sampling runs were employed. The convergence of the 
algorithm was monitored by plotting profiles of values 
generated sequentially during the Gibbs sampling, one 
plot for each of the four unknown response parameters. A 
reasonably stationary behaviour of the four profiles was 
achieved after 100 runs, although substantial cyclicity 
persisted. Subsequent samples were picked up at a rate of 
one out of every five to reduce autocorrelation. The 
obtained predictive distribution of subsequent WBC count 
evolution over cycles 2 to 5 is represented in Fig.Sb by a 
cloud of points. Big points represent actual observations. 
One may note that the prediction fits the actually observed 
patient's data much better than the population-based 
prediction of Fig. Sa. Moreover, the good fit between 
actual observations made in cycles 2 to 5 and the 
corresponding prediction indicates that the patient is 
"responding as expected". Any discrepancy may lead to a 
decision (e.g. to change therapy) and can also be used to 
update response parameters. 
Fig.Sc displays the prediction of the patient's response 
over cycles 4 and 5, based on data of cycles 1 to 3. 
Fig.Sd shows the evolution of the estimated posterior 
distribution for parameter a over the cycles of therapy. 
Note that the sequential updates gradually shift our belief 
towards the highest value for parameter a, thus 
strengthening our opinion that the patient is "very 
sensitive". Another useful summary would be a plot of 
percentile curves for posteriors of interest. 
7. CONCLUSIONS 
We have described an approach to therapy monitoring that 
we hope of potential usefulness in many areas of clinical 
monitoring, such as short-term drug delivery, medium­
term therapy managing and long-term monitoring of 
chronic diseases. An important characteristic of this 
approach is the capability of learning at a population level 
and adapting to a specific patient. 
In the future we intend to explore, in different application 
areas, the possibility of developing these models into 
even larger networks by extending them to include 
processes that develop on different temporal scales, such 
as when short-term drug delivery and medium-term 
clinical outcomes are taken into account jointly. A 
suitable conditional independence structure would make a 
large network model manageable, allowing its various 
portions to be studied individually, so that different areas 
of expertise might be cooperatively brought to bear. 
An investigation of the possibilities to combine the 
modelling approach proposed in this paper with other 
approaches, such as compartmental modelling, provides 
much scope for further work. In particular, compartmental 
modeling of the underlying drug metabolism might 
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provide an essential tool for achieving meaningful and 
parsimonious parametrisations of the response 
relationship to be modelled. This would allow patho­
physiological knowledge to be brought to bear, and would 
be particularly useful when multiple response curves, 
generated by the same underlying metabolic dynamics are 
involved. 
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